One of the most critical effects of the melanoma oncogene MITF is therefore in therapy resistance—a phenomenon in cancer cells which also strongly implicates GH action [14], especially in metastatic (stage IV) melanoma [21], which also displays the highest GHR expression in the NCI60 panel [6] of 60 human tumor cell lines of eleven different cancer types. This evidence concerns the gene MITF and neoplasm.